- Home
- ATNM vs VTVT Comparison
ATNM vs VTVT Comparison
Compare ATNM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- VTVT
- Stock Information
- Founded
- ATNM 2000
- VTVT 2015
- Country
- ATNM United States
- VTVT United States
- Employees
- ATNM N/A
- VTVT N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- VTVT Health Care
- Exchange
- ATNM Nasdaq
- VTVT Nasdaq
- Market Cap
- ATNM 49.0M
- VTVT 41.9M
- IPO Year
- ATNM N/A
- VTVT 2015
- Fundamental
- Price
- ATNM $1.72
- VTVT $16.00
- Analyst Decision
- ATNM Strong Buy
- VTVT Strong Buy
- Analyst Count
- ATNM 2
- VTVT 2
- Target Price
- ATNM $4.50
- VTVT $35.50
- AVG Volume (30 Days)
- ATNM 176.2K
- VTVT 1.4K
- Earning Date
- ATNM 08-08-2025
- VTVT 08-12-2025
- Dividend Yield
- ATNM N/A
- VTVT N/A
- EPS Growth
- ATNM N/A
- VTVT N/A
- EPS
- ATNM N/A
- VTVT N/A
- Revenue
- ATNM N/A
- VTVT $17,000.00
- Revenue This Year
- ATNM N/A
- VTVT N/A
- Revenue Next Year
- ATNM N/A
- VTVT N/A
- P/E Ratio
- ATNM N/A
- VTVT N/A
- Revenue Growth
- ATNM N/A
- VTVT N/A
- 52 Week Low
- ATNM $1.03
- VTVT $12.62
- 52 Week High
- ATNM $2.41
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- ATNM 54.44
- VTVT 55.62
- Support Level
- ATNM $1.60
- VTVT $14.98
- Resistance Level
- ATNM $1.79
- VTVT $15.84
- Average True Range (ATR)
- ATNM 0.10
- VTVT 0.26
- MACD
- ATNM 0.01
- VTVT 0.15
- Stochastic Oscillator
- ATNM 76.25
- VTVT 99.50
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.